Is the Kiora Pharmaceuticals (KPRX) investment thesis intact?

Yes. Readouts currently rates the Kiora Pharmaceuticals Thesis Intact. Kiora adds oral KIO-401; financing becomes central alongside partnered KIO-301.

What is the next catalyst for Kiora Pharmaceuticals (KPRX)?

The next dated event is Interim results for KIO-104, expected late 2026, as stated by the company. Also ahead: Phase 2 topline results (ABACUS-2) for KIO-301, expected Q3 2027.

How long will Kiora Pharmaceuticals' cash last?

Kiora Pharmaceuticals has said its cash will fund operations into late 2028 (guidance as of August 7, 2026).

KPRXKiora Pharmaceuticals, Inc.

Market reactionShares rose 19% on Nov 2.

IntactLast material event Aug 7, 2026 · Updated Oct 29, 2026

Kiora adds oral KIO-401; financing becomes central alongside partnered KIO-301

Kiora Pharmaceuticals develops KIO-401, a pill licensed from Senju to protect vision after retinal artery blockage, and KIO-301, a Théa-partnered eye injection for late-stage retinitis pigmentosa; KIO-104 was discontinued; none is approved.

Kiora retains partner-funded KIO-301 for late-stage retinitis pigmentosa, with ABACUS-2 topline expected in the third quarter of 2027. It now prioritizes oral KIO-401 for acute retinal ischemia and has discontinued KIO-104 development. KIO-401 adds late-stage potential but requires financing and regulatory alignment; its Japanese overall primary endpoint only trended positive. Earlier runway guidance into late 2028 depended on the operating plan and reimbursements, not funding the expanded program.

Thesis checklist

2 risks need attention

Select a row for evidence

What must be trueStateNext proof

ABACUS-2 shows vision gainsAwaiting evidenceABACUS-2 topline results, expected in the third quarter of 2027.Next: ABACUS-2 topline results, expected in the third quarter of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

KLARITY shows KIO-104 activityAt riskKLARITY enrolled-patient results and whether they attract an out-licensing partner.Next: KLARITY enrolled-patient results and whether they attract an out-licensing partner.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash and partners fund the planAt riskFinancing terms and updated runway guidance incorporating licensing obligations and planned clinical spending.Next: Financing terms and updated runway guidance incorporating licensing obligations and planned clinical spending.

Why it is in this state

The evidence, what would weaken it and the source filing

KIO-401 Phase 3 starts in CRAOAwaiting evidenceRegulators' agreement on the Phase 3 design and trial start, targeted for 2027.Next: Regulators' agreement on the Phase 3 design and trial start, targeted for 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Can Kiora finance the expanded development plan?

Tests: Cash and partners fund the plan

At the next financing or updated operating-plan disclosure.

Can financing cover KIO-401 licensing obligations and clinical development while preserving partnered KIO-301?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentFinancial

Aug 7, 2026

Kiora adds oral KIO-401; financing becomes central alongside partnered KIO-301

ChallengedClinical

-3.4%Mar 25, 2026

KIO-301's photoswitch mechanism targets vision restoration in advanced RP; Phase 2 ABACUS-2 data will determine whether early signals replicate at scale

ChallengedFinancial

+36.8%Jun 3, 2025

Senju Exclusive Option Agreement for KIO-301 Asia

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Retinitis Pigmentosa

KIO-301 · 1 upcoming

Phase 2 Data: ToplineABACUS-2

Early 2027Q3 2027

Macular edema· retinal inflammation

KIO-104 · 1 upcoming

Data: InterimKLARITY

late 2026

Central retinal artery occlusion· acute

KIO-401 · 2 upcoming

Phase 3 Study Initiation

2027

technology transfer from Senju and milestone payment

2027

Epilepsy· exploratory CNS indications

KIO-300 · 1 upcoming

exploratory R&D and neurological disorders

TBD

Non-arteritic anterior ischemic optic neuropathy

KIO-401 · 1 upcoming

Phase 2b Study Initiation

2028

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Kiora Pharmaceuticals (KPRX) investment thesis intact?: Yes. Readouts currently rates the Kiora Pharmaceuticals Thesis Intact. Kiora adds oral KIO-401; financing becomes central alongside partnered KIO-301.
What is the next catalyst for Kiora Pharmaceuticals (KPRX)?: The next dated event is Interim results for KIO-104, expected late 2026, as stated by the company. Also ahead: Phase 2 topline results (ABACUS-2) for KIO-301, expected Q3 2027.
How long will Kiora Pharmaceuticals' cash last?: Kiora Pharmaceuticals has said its cash will fund operations into late 2028 (guidance as of August 7, 2026).

Other companies we cover in these diseases

Macular edema: BioAge Labs (BIOA)Kodiak Sciences (KOD)Ocugen (OCGN)Palatin Technologies (PTN)
Retinitis Pigmentosa: Opus Genetics (IRD)
Stargardt disease: Belite Bio (BLTE)

Disease areas: Eye diseases, Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

7 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.